Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

Genzyme Corporation

Sanofi Pasteur Sa

Boehringer Ingelheim Vetmedica Gmbh

Sanofi Pasteur Inc.

Guillaume Rigaut

Noel Joseph Francois Detraz

Alexis Guy André Lucien Parisot

Pradeep K Dhal

Jean Haensler

Philippe Talaga

Marie Garinot

Christine Michele Pierrette Andreoni

Patricia Probeck-Quellec

Celine Loss-Dunod

Karelle De Luca

Lydie Remolue

Jean-François Cotte

Véronique Chambon

Pradeep K Dahl

Noël Joseph François Detraz

Alexis Guy Parisot

Pradeep Dahl

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.

Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants

The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative-containing multi-dose formulations. The preservative-containing multi-dose formulations exhibit resistance to one or more contaminating microorganisms, and have advantageous properties with respect to long term stability of biological and small molecule active ingredients.

Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative

The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Vaccine formulations comprising saponin-containing adjuvants

The invention relates to flow-through devices for mixing fluids and uses thereof for mixing and for lysing cells to release biological compounds of interest. The invention particularly encompasses flow-through methods for mixing and chemical methods for the isolation and purification of plasmid DNA from cell culture.

Mixing devices for chemical lysis of cells

The present invention encompasses a flow-through dispersion device for the dispersion of cell aggregates, the device comprising a first or upstream inlet obstacle and a second or downstream outlet obstacle, each obstacle having at least one traversing hole wherein no two holes align. Between the two obstacles is a turbulence chamber, such that when a cell suspension is passed through the inlet holes, into the chamber and then exits the second obstacle, the turbulence within the chamber disrupts and disperses cell aggregates. The device optionally may have more than two obstacles and turbulence chambers and multiple units may be placed in series to increase the amount of turbulence and time applied to a volume of cells. The invention further encompasses methods of using the device to disperse cell aggregates, and methods of culturing cells that involve seeding cultures and maintaining dispersed individual cells.

Dispersion devices for aggregates

Growing community of inventors

Lyons, France

Guillaume Rigaut